Innate Pharma
IPHA
16 hedge funds and large institutions have $6.52M invested in Innate Pharma in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 7 closing their positions.
12% more capital invested
Capital invested by funds: $5.82M → $6.52M (+$702K)
0.56% more ownership
Funds ownership: 1.19% → 1.75% (+0.56%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
11% less funds holding
Funds holding: 18 → 16 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.11M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$979K |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
+$499K |
| 4 |
Optiver Holding
Amsterdam,
Netherlands
|
+$416K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.16M |
| 2 |
AAA
Affinity Asset Advisors
New York
|
-$771K |
| 3 |
VF
Virtu Financial
New York
|
-$521K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$124K |
| 5 |
LPL Financial
San Diego,
California
|
-$114K |
IPHA Hedge Fund Activity: Q4 2021 in Review
16 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q4 2021, worth a combined $6.52M — up 12% from $5.82M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IPHA and 5 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 5 added.
The largest buyer was BlackRock, opening a new position worth an estimated $2.11M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.16M sold.
- 16 institutional investors held Innate Pharma (IPHA) as of Q4 2021, down from 18 in Q3 2021.
- Funds reported $6.52M of Innate Pharma stock for Q4 2021, up 12% quarter-over-quarter.
- 5 funds opened new Innate Pharma positions in Q4 2021 and 7 closed out, a net change of -2 holders.
- The largest Innate Pharma buyer in Q4 2021 was BlackRock, an estimated $2.11M added.
- The largest Innate Pharma seller in Q4 2021 was Balyasny Asset Management, an estimated $1.16M sold.
Based on aggregated 13F filings for Q4 2021.